Monographie - Daunorubicin/cytarabine liposomale - Stabilis 4.0

Last update :
20/03/2025

Anticancer drug

Daunorubicin/cytarabine liposomale

injection

Stability in solutions

Stability of mixtures

Factors which affect stability

Compatibility

Route of administration

References

pdf

Tradename

Tradename

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Vyxeos

France, Germany, Great Britain, Hungary, Ireland, Italy, Norway, Romania, Spain, Sweden

Stability in solutions

injection

Stability in solutions : Daunorubicin/cytarabine liposomale

Container

Solvent

Concentration

Temperature

Storage

Duration of stability

References

Glass

Water for Injection

2.2 / 5 mg/mL

2-8°C

Not specified

4

Hour

Manufacturer's stability data

Glass

Water for Injection

2.2 / 5 mg/mL

2-8°C

Not specified

4

Hour

Manufacturer's stability data

Polyolefine

NaCl 0,9% or Glucose 5%

0.087 / 0.195 mg/mL

2-8°C

Not specified

4

Hour

Manufacturer's stability data

Polyolefine

NaCl 0,9% or Glucose 5%

0.176 / 0.4 mg/mL

2-8°C

Not specified

4

Hour

Manufacturer's stability data

Mentions Légales